Nagano, Japan. Dr. William Jia, Virogin Biotech CSO, will present “New strategies for oncolytic virotherapy: turning anti-viral immunity to anti-tumor” at a session on Novel Viral Platforms on October 24.
To date, we have raised over $300M USD to support our efforts in developing best-in-class therapeutics for patients with unmet medical needs.
Nagano, Japan. Dr. William Jia, Virogin Biotech CSO, will present “New strategies for oncolytic virotherapy: turning anti-viral immunity to anti-tumor” at a session on Novel Viral Platforms on October 24.
Leipzig, Germany. Jeff Lange, Virogin Biotech EVP Business Development, will present an overview of Virogin Biotech and its OV platforms and will participate in one-to-one partnering meetings.
Boston, Massachusetts. Jeff Lange, Virogin Biotech EVP Business Development, will present “New strategies for oncolytic virotherapy: turning anti-viral immunity to anti-tumor” at a session on Novel Combination Therapies to Maximize Anti-Cancer Effectiveness on December 6.
